Transcript
www.pharminvent.com November2010
Pharmacovigilance
Regulatory Science
Risk Management
Risk-benefit optimisation
Advanced Therapies
Biologics
Biosimilars
Generics
Small molecules
Centrally authorised
Decentralised procedures
Mutually recognised
Nationally authorised